Healio: Top in Cardiology: Highlights from the American College of Cardiology Scientific Session

Adults with obesity-related heart failure and diabetes saw improvements in heart failure symptoms and physical function with semaglutide 2.4 mg compared with placebo, a recent study showed.

The data were presented at the American College of Cardiology Scientific Session.

“This study offers clear confirmation ... of very large benefits on symptoms and physical limitations due to HF with semaglutide vs. placebo,” Mikhail Kosiborod, MD, FACC, FAHA, a cardiologist at Saint Luke’s Mid America Heart Institute and professor of medicine at the University of Missouri-Kansas City School of Medicine, told Healio.

Read the full Healio article: Top in Cardiology: Highlights from the American College of Cardiology Scientific Session

Related Content

Apr. 8, 2024

MEDIA COVERAGE: Obesity Medication Proves Effective in Treating Patients with Obesity-Related Heart Failure and Type 2 Diabetes
A new study led by Dr. Mikhail Kosiborod found patients with obesity-related heart failure and type 2 diabetes had significant improvement in symptoms and physical limitations when taking semaglutide.
Apr. 10, 2024

U.S. News & World Report: Wegovy Helps Those With Both Diabetes, Heart Failure: Study
For people struggling with both diabetes and a common type of heart failure, the weight-loss drug Wegovy may do more for their health than help them shed pounds, new research suggests.
Apr. 8, 2024

CNN: Weight-Loss Drug Wegovy Offers Benefits for People with Diabetes and Common Form of Heart Failure, Study Finds
The popular weight loss drug Wegovy seems to provide more health benefits for people who have diabetes and a common kind of heart failure than just helping take off the pounds, according to the results from the STEP HFpEF DM trial.